SAMPLE REPORTCity Hospital
123 City AvenueAnywhere, ST 12345
LCLS Specimen Number:
Patient Name:
Date of Birth:
Gender:Patient ID:
Lab Number:
Indications:123-456-7891-0
Doe, Jane00/00/1975
FAccount Number: 12345678
Ordering Physician: Ordering Doctor, MD
Specimen Type: POC
Date Collected: 01/31/2012
Date Received: 02/02/2012
CoPath Number:
Spontaneous pregnancy loss at 9 weeks Client Reference:

Test: POC/Tissue Microarray
Genotyping Targets: 2695000

Date Reported: 02/11/2012
Array Type: SNPMICROARRAY RESULT: NORMAL FEMALEINTERPRETATION:
arr(1-22,X)x2
The whole genome chromosome SNP microarray (REVEAL) analysis wasnormal. No significant changes in the 2.695 million region specific
SNP and structural targets were detected within the thresholds andspecifications indicated below. In addition, no admixture of fetal andmaternal DNA was noted.
Methodology
SNP microarray analysis was performed using the Affymetrix Cytoscan HD platform which uses over 743,000 SNP probes
and 1,953,000 NPCN probes with a median spacing of 0.88 kb. 250ng of total genomic DNA extracted from lymphocytes
was digested with NspI and then ligated to NspI adaptors, respectively, and amplified using Titanium Taq with a GeneAmp
PCR System 9700. PCR products were purified using AMPure beads and quantified using NanoDrop 8000. Purified DNA
was fragmented and biotin labeled and hybridized to the Affymetrix Cytoscan HD GeneChip. Data was analyzed using
Chromosome Analysis Suite. The analysis is based on the GRCh37/hg19 assembly.
Positive evaluation criteria include:* Copy numbers gains >2 Mb and losses >1 Mb, including at least one OMIM annotated gene are reported in this analysis.
* Gains/losses of >100 Kb within a custom clinically significant gene set. On request, candidate genes can be analyzed at amuch lower threshold, depending on the gene specific marker density.
* DNA copy gain/loss of whole chromosomes with at least 10% fetal origin of the DNA tested.
* Maternal cell contamination (MCC) is detected by comparison of abnormal dosage allele combinations as well as normal
dosage mixes of fetal and maternal alleles.
* Complete moles are accurately detected by the presence of whole genome allele homozygosity (~50% hmz in rare dispermymoles).
* Triploid tissue that normalizes to 2 copies in standard array analysis, are detectable in this allele specific microarray by 2:1
heterozygote allele ratios generated within each chromosome by the software.
Truly balanced chromosome alterations (generally not the cause of miscarriage) will not be detected by this analysis. The
threshold for mosaicism is variable, depending on the size of segment. Empiric studies have detected whole chromosome 22
mosaicism below 10.0%. CNVs cited in the Database of Genomic Variants are not reported.
This test was developed and its performance characteristics determined by Laboratory Corporation of America Holdings(LabCorp). It has not been cleared or approved by the Food and Drug Administration(FDA). The FDA has determined thatsuch clearance or approval is not necessary.

Page 1 of 2

SAMPLE REPORTCity Hospital
123 City Avenue
Anywhere, ST 12345
LCLS Specimen Number:
Patient Name:
Date of Birth:
Gender:Patient ID:
Lab Number:
Indications:123-456-7891-0
Doe, Jane00/00/1975
FAccount Number: 12345678
Ordering Physician: Ordering Doctor, MD
Specimen Type: POC
Date Collected: 01/31/2012
Date Received: 02/02/2012
CoPath Number:
Spontaneous pregnancy loss at 9 weeks Client Reference:__________________________________________________

Board Certified Cytogeneticist
Test Site: LabCorp
1904 Alexander Drive, RTP, NC, 27709-0153 (800) 533-0567

This document contains private and confidential health information protected by state and federal law.

Reveal® is a registered service mark of Esoterix Genetic Laboratories, LLC.
Integrated Genetics is a business unit of Esoterix Genetic Laboratories, LLC,a wholly-owned subsidiary of Laboratory Corporation of America Holdings.
©2012 Laboratory Corporation of America® Holdings. All rights reserved.
rep-469-v1-0712

Page 2 of 2